×
Search your requirement
Search your requirement
Home
Press Releases
Submit Release
Events
Reach Us
Social media
Search
Home
Press Releases
Submit Release
Events
Reach Us
Search
MilliporeSigma receives the industry's first EXCiPACT certification for cell culture media manufacturing
Ibex Medical Analytics achieves notable milestones with its AI-first approach to cancer diagnostics
Albertsons Companies pharmacies now offer COVID and flu vaccines to help protect communities this respiratory virus season
OmniSYS rebrands as XiFin Pharmacy Solutions, launches Pharmacy Payor Rate Transparency Monitor, and earns the Pharmacy 500 Award
Gilead’s Livdelzi (Seladelpar) receives FDA accelerated approval for primary biliary cholangitis
ProJenX announces the formation of its Clinical Advisory Board
Citius Pharmaceuticals' LYMPHIR™ wins FDA approval for relapsed/refractory cutaneous T-cell lymphoma
NewAmsterdam Pharma announces positive topline data from the Phase 3 BROOKLYN trial of Obicetrapib in heterozygous familial hypercholesterolemia patients
Cygnus Technologies and TriLink BioTechnologies® collaborate to launch AccuRes™ Host Cell DNA Quantification Kits
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules.
Updated flu and COVID-19 vaccinations are now available at CVS Pharmacy® and MinuteClinic
FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma
Featured Press Releases
Dr. Jonathan Sadeh, ex-SVP of Immunology R&D at Bristol-Myers Squibb, joins Scinai Immunotherapeutics' Scientific Advisory Board
Trailblazing 3D human liver models yield accurate MASH phenotype
24 Jan 2024
Viscient Biosciences ("Viscient") announced that its scientists, along with collaborators from
...
ProteoNic unveils Early Access Program, boosting viral vector titers with LV-2G UNic® technology
Improved Pharma Brings Onboard Micro-DSC Hot-Stage System
Immorta Bio Reports Successful Lung Cancer Growth Inhibition by Senolytic Immunotherapy SenoVax™
Transposon to share Phase 2 results of TPN-101 for C9orf72-related ALS/FTD at ALS ONE Research Symposium.
Matisse Pharmaceuticals receives INN for M6229, recognizing it as a first-in-class drug, isupartob sodium
By
Matisse Pharmaceuticals
Matisse Pharmaceuticals
15 Dec 2025
Sapio Sciences Collaborates with the Wellcome Sanger Institute on Transforming Digital Laboratories
By
Sapio Sciences
Sapio Sciences
11 Dec 2025
Medra Raises $52 Million in Series A Funding to Build Physical AI Scientists
By
Medra
Medra
11 Dec 2025
Voranigo® (vorasidenib) from Servier has received multiple regional Prix Galien Awards
By
Servier
Servier
09 Dec 2025
FIZE Medical, in an exclusive deal with Asahi Kasei Medical, has launched the FIZE kUO® System in Japan
By
FIZE Medical
FIZE Medical
09 Dec 2025
GMA with MOVIVA®: Setting New Standards in Endoscopic Bariatric Treatment.
By
Erbe Elektromedizin GmbH
Erbe Elektromedizin GmbH
03 Dec 2025
Log in
Username
Show
Remember Me
Log in
Create an account
Forgot your username?
Forgot your password?
Most Popular
Sensitech acquires Berlinger & Co. to expand life sciences cold chain solutions
By
Sensitech Inc
Aug 02
Cognito Therapeutics Presents Spectris™ Data on Brain Structural Maintenance in Alzheimer’s at AD/PD™ 2025
By
Cognito Therapeutics
Apr 02
FDA Approves ZOLL’s Zenix Monitor/Defibrillator, Elevating Asahi Kasei’s Critical Care Solutions
By
Asahi Kasei Corp.
Oct 13
January
2026
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
User Area
Login page
Registration
Edit Profile
Forgot Password
Discover
About Us
Terms Of Use
Privacy Policy
FAQs
Engage with Us
Search on Site
Post Press Release
Promote Brand
List Your Event
Subscribe for e-Newsletter Monthly
Subscribe to the Pharmaceutical Era newsletter to receive timely updates from your favorite products.
Email
I consent to subscribing to the selected email lists.
Enter the code below
Subscribe
1
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. To find out more, please click
here
.
I understand